Core Insights - He Yuan Bio experienced a significant decline of 8.02% in stock price on November 11, with a trading volume of 9.52 billion yuan [1] - The company reported a net financing outflow of 16.81 million yuan on the same day, with a total financing and securities balance of 403 million yuan [1] Group 1: Financial Performance - For the period from January to September 2025, He Yuan Bio achieved a revenue of 19.66 million yuan, representing a year-on-year decrease of 8.51% [2] - The net profit attributable to the parent company was -121 million yuan, reflecting a year-on-year decline of 8.44% [2] Group 2: Shareholder and Market Data - As of October 28, the number of shareholders for He Yuan Bio reached 47,100, an increase of 84,075% compared to the previous period [2] - The average number of circulating shares per shareholder decreased to 869 shares, down by 99.85% from the previous period [2] Group 3: Company Overview - He Yuan Bio, established on November 16, 2006, is located in Wuhan, Hubei Province, and specializes in the research, production, and sales of products using rice embryo cell recombinant protein expression technology [1] - The main business revenue composition includes 75.44% from recombinant human albumin and 24.56% from other products [1]
禾元生物11月11日获融资买入1.05亿元，融资余额4.03亿元